» Articles » PMID: 24120440

Sulforaphane Ameliorates the Development of Experimental Autoimmune Encephalomyelitis by Antagonizing Oxidative Stress and Th17-related Inflammation in Mice

Overview
Journal Exp Neurol
Specialty Neurology
Date 2013 Oct 15
PMID 24120440
Citations 70
Authors
Affiliations
Soon will be listed here.
Abstract

Sulforaphane (SFN) is an organosulfur compound present in vegetables and has potent anti-oxidant and anti-inflammatory activities. This study was aimed at investigating the effect of treatment with SFN on inflammation and oxidative stress, and the potential mechanisms underlying the action of SFN in experimental autoimmune encephalomyelitis (EAE) in C57BL/6 mice. Treatment with SFN significantly inhibited the development and severity of EAE in mice, accompanied by mitigating inflammatory infiltration and demyelination in the spinal cord of mice. The protective effect of SFN was associated with significantly improved distribution of claudin-5 and occludin, and decreased levels of MMP-9 expression, preserving the blood-brain barrier. Furthermore, the protection of SFN was also related to decreased levels of oxidative stress in the brains of mice by enhanced activation of the Nrf2/ARE pathway and increased levels of anti-oxidant HO-1 and NQO1 expression. In addition, treatment with SFN inhibited antigen-specific Th17 responses and enhanced IL-10 responses. Our data indicated that treatment with SFN inhibited EAE development and severity in mice by its anti-oxidant activity and antagonizing autoimmune inflammation. Our findings suggest that SFN and its analogues may be promising reagents for intervention of multiple sclerosis and other autoimmune diseases.

Citing Articles

Endogenous extraction yielded high quality sulforaphane from broccoli sprouts unveils potent antioxidant and anti-Alzheimer's activities.

Uthaman S, Kang W, Park J, Kim S, Le D, Oh S Heliyon. 2025; 11(4):e42673.

PMID: 40034321 PMC: 11875816. DOI: 10.1016/j.heliyon.2025.e42673.


Molecular mechanisms of sulforaphane in Alzheimer's disease: insights from an in-silico study.

Vu G, Nguyen H In Silico Pharmacol. 2024; 12(2):96.

PMID: 39493676 PMC: 11530583. DOI: 10.1007/s40203-024-00267-4.


Antioxidant Therapies in the Treatment of Multiple Sclerosis.

Jimenez-Jimenez F, Alonso-Navarro H, Salgado-Camara P, Garcia-Martin E, Agundez J Biomolecules. 2024; 14(10).

PMID: 39456199 PMC: 11506420. DOI: 10.3390/biom14101266.


Targeting the NRF2 pathway for disease modification in neurodegenerative diseases: mechanisms and therapeutic implications.

Mayer C, Riera-Ponsati L, Kauppinen S, Klitgaard H, Erler J, Hansen S Front Pharmacol. 2024; 15:1437939.

PMID: 39119604 PMC: 11306042. DOI: 10.3389/fphar.2024.1437939.


Hydrogen sulfide reduces oxidative stress in Huntington's disease via Nrf2.

Jiang Z, Liu D, Li T, Gai C, Xin D, Zhao Y Neural Regen Res. 2024; 20(6):1776-1788.

PMID: 39104115 PMC: 11688542. DOI: 10.4103/NRR.NRR-D-23-01051.